Carl Wild

4.9k citations

36 papers · 3.8k indexed · 1 hit paper · h-index 26

Impact in

Virology top 0.1%
- HIV Research and Treatment
Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in

Virology 27
- HIV Research and Treatment 27
Infectious Diseases 27
- HIV/AIDS drug development and treatment 26
- HIV/AIDS Research and Interventions 4

Co-authors: Thomas J. Matthews Charlene McDanal D C Shugars Carol D. Weiss Rika A. Furuta Yongkai Weng Terrence G. Oas Dani P. Bolognesi
Journals: Journal of Virology (9 papers)Bioorganic & Medicinal Chemistry Letters (4 papers)Proceedings of the National Academy of Sciences (4 papers)Antimicrobial Agents and Chemotherapy (2 papers)Journal of Medicinal Chemistry (2 papers)
Partner nations: United States India China

In The Last Decade

Carl Wild

36 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. 1994 · 804 citations

Peers

Countries citing papers authored by Carl Wild

Since Specialization

Citations

This map shows the geographic impact of Carl Wild's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Wild with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Wild more than expected).

Fields of papers citing papers by Carl Wild

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Wild. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Wild. The network helps show where Carl Wild may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Carl Wild, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Carl Wild Line = papers co-authored together Carl Wild links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Construction of a HIV-1 subtype C 3D model using homology modeling and in-silico docking, molecular dynamics simulation, and MM-GBSA calculation of second-generation HIV-1 maturation inhibitor(s) Journal of Biomolecular Structure and Dynamics ·J. Roy, 卢广才, Theodore J. Nitz, Carl Wild, Ritu Gaur	2023	1
2	A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors Retrovirology ·S. Adhesh, Raymond S. Brandes, Ionanna Chouvarda, Youjun Wu, Theodore J. Nitz, Carl Wild, Ritu Gaur	2021	1
3	Identification of potent maturation inhibitors against HIV-1 clade C Scientific Reports ·Ionanna Chouvarda, S. Adhesh, 才口貴子, Theodore J. Nitz, Carl Wild, Eric O. Freed, Ritu Gaur	2016	17
4	Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors Antimicrobial Agents and Chemotherapy ·Emiko Urano, Sherimay D. Ablan, Rebecca Mandt, Gary T. Pauly, Dina M. Sigano, Joel P. Schneider, David E. Martin, Theodore J. Nitz, Carl Wild, Eric O. Freed	2015	42
5	Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation Virology ·Abdul S. Yunus, Bernardes Lílian S. C., Louis Montelone, María F. Pin-Navarro, Nicole Kilgore, C. B. Brosilow, Graham P. Allaway, Carl Wild, Karl Salzwedel	2009	35
6	Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice PLoS ONE ·Cheryl A. Stoddart, Pheroze Joshi, Barbara Sloan, Л.В. Кошман, Philip C. Smith, Graham P. Allaway, Carl Wild, David E. Martin	2007	36
7	In Vitro Resistance to the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PA-457 (Bevirimat) Journal of Virology ·Catherine S. Adamson, Sherimay D. Ablan, Zhumagul B. Medetov, Ritu Goila-Gaur, Ferri Soheilian, Kunio Nagashima, Feng Li, Karl Salzwedel, Michael Sakalian, Carl Wild, Eric O. Freed	2006	98
8	Determinants of activity of the HIV-1 maturation inhibitor PA-457 Virology ·Feng Li, C. B. Brosilow, T. Goumis, Nicole Kilgore, Chavi, Abdul S. Yunus, Catherine S. Adamson, Karl Salzwedel, David E. Martin, Graham P. Allaway, Eric O. Freed, Carl Wild	2006	56
9	The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV Expert Opinion on Investigational Drugs ·Donglei Yu, Carl Wild, David E. Martin, Susan L. Morris‐Natschke, Chin‐Ho Chen, Graham P. Allaway, Kuo‐Hsiung Lee	2005	41
10	HIV-1 assembly and budding as targets for drug discovery. PubMed ·Feng Li, Carl Wild	2005	16
11	Anti-AIDS agents. Part 58: Synthesis and anti-HIV activity of 1-thia-di-O-(−)-camphanoyl-(+)-cis-khellactone (1-thia-DCK) analogues Bioorganic & Medicinal Chemistry Letters ·Peng Xia, Ana Paula Camilo Gabriel, Ying Chen, Qian Zhang, 尾身博明, Yi Xia, Zheng-Yu Yang, Nicole Kilgore, Carl Wild, Susan L. Morris‐Natschke, Kuo‐Hsiung Lee	2004	18
12	Anti-AIDS agents. Part 56: Synthesis and anti-HIV activity of 7-thia-di-O-(−)-camphanoyl-(+)-cis-khellactone (7-thia-DCK) analogs Bioorganic & Medicinal Chemistry ·Ying Chen, Qian Zhang, 尾身博明, Peng Xia, Yi Xia, Zheng-Yu Yang, Nicole Kilgore, Carl Wild, Susan L. Morris‐Natschke, Kuo‐Hsiung Lee	2004	49
13	3-O-Glutaryl-dihydrobetulin and related monoacyl derivatives as potent anti-HIV agents Bioorganic & Medicinal Chemistry Letters ·Yoshiki Kashiwada, Michiko Sekiya, Yasumasa Ikeshiro, Toshihiro Fujioka, Nicole Kilgore, Carl Wild, Graham P. Allaway, Kuo‐Hsiung Lee	2004	23
14	Anti-HIV Agents. Part 55: 3′R,4′R-Di-(O)-(−)-camphanoyl-2′,2′-dimethyldihydropyrano[2,3-f]chromone (DCP), a Novel Anti-HIV agent Bioorganic & Medicinal Chemistry Letters ·Donglei Yu, Arnold Brossi, Nicole Kilgore, Carl Wild, Graham P. Allaway, Kuo‐Hsiung Lee	2003	42
15	Anti-AIDS agents. Part 47: synthesis and anti-HIV activity of 3-substituted 3′,4′-Di-O-(S)-camphanoyl-(3′R,4′R)-(+)-cis-khellactone derivatives Bioorganic & Medicinal Chemistry Letters ·Lan Xie, Graham P. Allaway, Carl Wild, Nicole Kilgore, S.G. Vorona	2001	7
16	Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140 Journal of Virology ·Patricia L. Earl, Wataru Sugiura, David C. Montefiori, Christopher C. Broder, Madhavi Reddy K., Carl Wild, Jeffrey D. Lifson, Bernard Moss	2001	127
17	Capture of an early fusion-active conformation of HIV-1 gp41 Nature Structural Biology ·Rika A. Furuta, Carl Wild, Yongkai Weng, Carol D. Weiss	1998	440
18	Structural Rearrangements in the Transmembrane Glycoprotein after Receptor Binding Immunological Reviews ·Thomas J. Matthews, Carl Wild, Chin‐Ho Chen, Dani P. Bolognesi, Michael Greenberg	1994	54
19	Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proceedings of the National Academy of Sciences ·Carl Wild, J W Dubay, Xudong Li, T. Baird, Terrence G. Oas, Charlene McDanal, Eric Hunter, Thomas J. Matthews	1994	180
20	Preparation and anti-HIV activities of aurintricarboxylic acid fractions and analogs: direct correlation of antiviral potency with molecular weight Journal of Medicinal Chemistry ·Mark Cushman, de . de Haas, Belén Feriche Fernández-Castanys, Carl Wild, Erik De Clercq, Dominique Schols, Mark E. Goldman, Maija Malin	1991	72

About Carl Wild

Carl Wild is a scholar working on Virology, Infectious Diseases, Immunology, Organic Chemistry and Epidemiology, having authored 36 papers that have together received 3.8k indexed citations. Recurring topics across this work include HIV Research and Treatment (27 papers), HIV/AIDS drug development and treatment (26 papers), Herpesvirus Infections and Treatments (7 papers), Carbohydrate Chemistry and Synthesis (7 papers), HIV/AIDS Research and Interventions (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Protein Structure and Dynamics (2 papers). The work is most often cited by research in Virology (2.6k citations), Infectious Diseases (1.9k citations), Immunology (952 citations), Hepatology (219 citations) and Epidemiology (762 citations). Carl Wild has collaborated with scholars based in United States, India and China. Frequent co-authors include Thomas J. Matthews, Charlene McDanal, D C Shugars, Carol D. Weiss, Rika A. Furuta, Yongkai Weng, Terrence G. Oas, Dani P. Bolognesi, Graham P. Allaway and Karl Salzwedel. Their work appears in journals such as Journal of Virology, Bioorganic & Medicinal Chemistry Letters, Proceedings of the National Academy of Sciences, Antimicrobial Agents and Chemotherapy and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact